Stock Analyses

Model-driven valuations for thousands of US-listed stocks, built from SEC EDGAR filings. Click any card to see the full analysis.

All sectors 6,479 Financial Services 1,900 Healthcare 1,116 Technology 1,079 Industrials 668 Consumer Cyclical 490 Basic Materials 337 Consumer Defensive 248 Communication Services 213 Utilities 183 Energy 165 Real Estate 80

1,116 stocks · page 10 of 19

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.

Jasper Therapeutics, Inc.

JUPITER NEUROSCIENCES, INC.

Market implies +135.9%/yr vs model +15.0% · above model

Market implies +6.2%/yr vs model +15.0% · below model

KalVista Pharmaceuticals, Inc.

Market implies +34.7%/yr vs model +15.0% · above model

Kairos Pharma, LTD.

KEWAUNEE SCIENTIFIC CORP /DE/

Deeply undervalued

Discount 57% Return to IV: +134.9%

Market implies -4.1%/yr vs model +12.1% · below model

Keysight Technologies, Inc.

Deeply overvalued

Premium +299% Return to IV: -74.9%

Owner yield 2.0% 10-yr IRR -3.2% · moderate

Market implies +25.4%/yr vs model +6.4% · above model

ORTHOPEDIATRICS CORP

Discount 8% Return to IV: +9.1%

Market implies -3.4%/yr vs model +24.6% · below model

Kailera Therapeutics, Inc.

Kalaris Therapeutics, Inc.

KESTRA MEDICAL TECHNOLOGIES, LTD.

Deeply overvalued

Premium +143% Return to IV: -58.9%

Market implies +15.8%/yr vs model +50.0% · below model

Kiniksa Pharmaceuticals International, plc

Deeply overvalued

Premium +58% Return to IV: -36.6%

Market implies +13.5%/yr vs model +10.0% · above model

Kodiak Sciences Inc.

KIORA PHARMACEUTICALS INC

Market implies -4.2%/yr vs model +15.0% · below model

Karyopharm Therapeutics Inc.

KORU Medical Systems, Inc.

Deeply overvalued

Premium +45% Return to IV: -30.9%

Market implies -1.8%/yr vs model +15.0% · below model

Keros Therapeutics, Inc.

Deeply undervalued

Discount 68% Return to IV: +212.8%

Market implies -10.5%/yr vs model +10.0% · below model

Korro Bio, Inc.

Market implies +95.2%/yr vs model +2.0% · above model

Krystal Biotech, Inc.

Deeply overvalued

Model IV$234.34

Premium +48% Return to IV: -32.5%

Market implies +24.1%/yr vs model +25.0% · in line

Pasithea Therapeutics Corp.

Market implies +25.5%/yr vs model +15.0% · above model

Pasithea Therapeutics Corp.

Market implies -24.4%/yr

Kura Oncology, Inc.

Market implies +40.3%/yr vs model +15.0% · above model

Kymera Therapeutics, Inc.

Market implies +93.1%/yr vs model +2.0% · above model

KYNTRA BIO, INC.

Market implies +42.3%/yr vs model +2.0% · above model

Kyverna Therapeutics, Inc.

KAZIA THERAPEUTICS LTD

STANDARD BIOTOOLS INC.

Market implies +36.7%/yr vs model +2.0% · above model

Lakewood-Amedex Biotherapeutics Inc.

LAKELAND INDUSTRIES INC

Deeply undervalued

Discount 70% Return to IV: +232.2%

Market implies -24.0%/yr vs model +15.0% · below model

LB PHARMACEUTICALS INC

Lineage Cell Therapeutics, Inc.

Market implies +28.1%/yr vs model +35.3% · below model

Legend Biotech Corp

LENZ Therapeutics, Inc.

Market implies +26.5%/yr vs model +15.0% · above model

Lexaria Bioscience Corp.

Market implies +77.1%/yr vs model +2.0% · above model

LIFECORE BIOMEDICAL, INC. DE

Deeply overvalued

Premium +44% Return to IV: -30.5%

Market implies +1.7%/yr vs model +6.3% · below model

Deeply undervalued

Discount 43% Return to IV: +75.0%

Market implies -6.8%/yr vs model +20.2% · below model

Discount 9% Return to IV: +9.8%

Market implies -10.9%/yr vs model +20.2% · below model

LifeStance Health Group, Inc.

Deeply overvalued

Premium +300% Return to IV: -75.0%

Market implies +32.4%/yr vs model +17.6% · above model

Lifevantage Corp

Deeply overvalued

Premium +31% Return to IV: -23.4%

Owner yield 10.1% 10-yr IRR 18.7% · steady

Market implies +6.6%/yr vs model +6.0% · in line

Market implies +33.8%/yr vs model +2.0% · above model

LIGAND PHARMACEUTICALS INC

Market implies +36.2%/yr vs model +2.6% · above model

Longeveron Inc.

Market implies +150.0%/yr vs model +14.1% · above model

LABCORP HOLDINGS INC.

Model IV$397.08

Discount 19% Return to IV: +23.8%

Owner yield 3.9% 10-yr IRR 6.2% · moderate

Market implies +3.6%/yr vs model +7.8% · below model

Liminatus Pharma, Inc.

Liminatus Pharma, Inc.

Lite Strategy, Inc.

Market implies -22.3%/yr vs model +15.0% · below model

Deeply overvalued

Premium +76% Return to IV: -43.2%

Owner yield 2.7% 10-yr IRR 2.0% · moderate

Market implies +14.5%/yr vs model +8.3% · above model

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Lakefront Biotherapeutics NV

Deeply overvalued

Model IV$748.36

Premium +54% Return to IV: -35.1%

Market implies +20.3%/yr vs model +19.2% · in line

LEMAITRE VASCULAR INC

Discount 13% Return to IV: +14.9%

Owner yield 2.6% 10-yr IRR 3.7% · moderate

Market implies +7.5%/yr vs model +11.9% · below model

Lumexa Imaging Holdings, Inc.

Lunai Bioworks Inc.

Deeply undervalued

Discount 25% Return to IV: +34.2%

Market implies -12.1%/yr vs model +15.0% · below model

Lantheus Holdings, Inc.

Deeply undervalued

Model IV$222.68

Discount 55% Return to IV: +121.1%

Owner yield 3.2% 10-yr IRR 8.5% · grower

Market implies +8.1%/yr vs model +25.0% · below model

Market implies +34.8%/yr vs model +2.0% · above model

Deeply overvalued

Premium +387% Return to IV: -79.5%

Market implies +20.7%/yr vs model +50.0% · below model

Larimar Therapeutics, Inc.